Skip to main content
SpringerLink
Log in

Mood Stabilizers, Anticonvulsants, and Anti-agitants

  • Chapter
  • First Online:
Clinical Psychopharmacology for Neurologists

  • 1061 Accesses

Abstract

This chapter addresses the use of mood stabilizers, including various anticonvulsants, for both FDA-approved and off-label uses in treating psychiatric disorders. Additionally, this chapter provides a focused overview of the management of adults with aggressive behaviors related to major psychiatric disorders, with an emphasis on conditions most likely to be encountered by neurologists. There are no FDA-approved pharmacological treatments of aggression, regardless of diagnosis or the origin of the behaviors. The treatments used to target aggression (beyond primary treatment of psychiatric disorders) are therefore off-label interventions and should be carefully considered after reviewing the available evidence. This chapter presents some of the relevant evidence supporting off-label pharmacological treatments targeting aggression related to specific diagnoses. Other sources provide more detailed overviews of the assessment and management of aggression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  2. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder [Electronic Version]. 2002 Retrieved July 21, 2015 from http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf.

  3. Quanbeck CD, Stone DC, Scott CL, et al. Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. J Clin Psychiatry. 2004;65(2):198–203.

    Article  PubMed  Google Scholar 

  4. Asnis GM, Kaplan ML, Hundorfean G, et al. Violence and homicidal behaviors in psychiatric disorders. Psychiatr Clin North Am. 1997;20(2):405–25.

    Article  CAS  PubMed  Google Scholar 

  5. McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry. 1999;60:S3–80.

    Article  Google Scholar 

  6. Wang Y, Xia J, Helfer B, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016;11:CD004028.

    PubMed  Google Scholar 

  7. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry. 1998;31:122–5.

    Article  CAS  PubMed  Google Scholar 

  8. Bender S, Linka T, Wolstein J, Gehendges S, Paulus HJ, Schall U, Gastpar M. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol. 2004;7(1):59–63.

    Article  CAS  PubMed  Google Scholar 

  9. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand. 1989;80:250–9.

    Article  CAS  PubMed  Google Scholar 

  10. Pavlovic ZM. Augmentation of clozapine’s antiaggressive properties with lamotrigine in a patient with chronic disorganized schizophrenia. J Clin Psychopharmacol. 2008;28(1):119–20.

    Article  PubMed  Google Scholar 

  11. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28(6):1186–97.

    Article  CAS  PubMed  Google Scholar 

  12. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409–13.

    Article  CAS  PubMed  Google Scholar 

  13. Newman WJ, McDermott BE. Beta blockers for violence prophylaxis – case reports. J Clin Psychopharmacol. 2011;31(6):785–7.

    Article  PubMed  Google Scholar 

  14. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62(3):199–203.

    Article  CAS  PubMed  Google Scholar 

  15. Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, Fartacek R, Lahmann C, Buschmann W, Tritt K, Bachler E, Mitterlehner F, Pedrosa Gil F, Leiberich P, Rother WK, Egger C. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26(1):61–6.

    Article  PubMed  Google Scholar 

  16. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1515–9.

    Article  CAS  PubMed  Google Scholar 

  17. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;6:CD005653.

    Google Scholar 

  18. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK. Lamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;9(3):287–91.

    Article  Google Scholar 

  19. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270–5.

    PubMed  Google Scholar 

  20. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986;47:423–6.

    PubMed  CAS  Google Scholar 

  21. Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis. 1986;174:290–4.

    Article  CAS  PubMed  Google Scholar 

  22. Greendyke RM, Berkner JP, Webster JC, Gulya A. Treatment of behavioral problems with pindolol. Psychosomatics. 1989;30(2):161–5.

    Article  CAS  PubMed  Google Scholar 

  23. Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschmann H, Ritsner M. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol. 2001;16(2):111–5.

    Article  CAS  PubMed  Google Scholar 

  24. Geracioti TD. Valproic acid treatment of episodic explosiveness related to brain injury. J Clin Psychiatry. 1994;55:416–7.

    PubMed  Google Scholar 

  25. Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry. 1995;56:430–1.

    PubMed  CAS  Google Scholar 

  26. Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired brain injury. Brain Inj. 1997;11:37–47.

    Article  CAS  PubMed  Google Scholar 

  27. Azouvi P, Jokic C, Attal N, Denys P, Markabi S, Bussel B. Carbamazepine in agitation and aggressive behavior following severe closed-head injury: results of an open trial. Brain Inj. 1999;13:797–804.

    Article  CAS  PubMed  Google Scholar 

  28. Haas JF, Cope DN. Neuropharmacologic management of behavior sequelae in head injury: a case report. Arch Phys Med Rehabil. 1985;66:472–4.

    PubMed  CAS  Google Scholar 

  29. Hornstein A, Seliger G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatr Clin Neurosci. 1989;1:446–7.

    Article  CAS  Google Scholar 

  30. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj. 2004;18:1–31.

    Article  PubMed  Google Scholar 

  31. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;2:CD005594.

    Google Scholar 

  32. Wilson MP, Pepper D, Currier GW, Holloam GH, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012;13:26–34.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium. Chest. 2007;132:624–36.

    Article  PubMed  Google Scholar 

  34. Craft M, Ismail IA, Krishnamurti D, Mathews J, Regan A, Seth RV, North PM. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry. 1987;150:685–9.

    Article  CAS  PubMed  Google Scholar 

  35. Spreat S, Behar D, Reneski B, Miazzo P. Lithium carbonate for aggression in mentally retarded persons. Compr Psychiatry. 1989;30:505–11.

    Article  CAS  PubMed  Google Scholar 

  36. Tyrer SP, Walsh A, Edwards DE, Berney TP, Stephens DA. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Prog Neuro-Psychopharmacol Biol Psychiatry. 1984;8:751–5.

    Article  CAS  Google Scholar 

  37. Mattes JA. Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis. 1992;180:601–2.

    Article  CAS  PubMed  Google Scholar 

  38. Amore M, Bertelli M, Villani D, Tamborini S, Rossi M. Olanzapine vs. risperidone in treating aggressive behaviors in adults with intellectual disability: a single blind study. J Intellect Disabil Res. 2011;55(2):210–8.

    Article  CAS  PubMed  Google Scholar 

  39. Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev. 2010;16(3):265–72.

    Article  PubMed  Google Scholar 

  40. Ruedrich SL, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard. 1990;95(1):110–9.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, USA

    William J. Newman MD

Authors
  1. William J. Newman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Newman MD .

Editor information

Editors and Affiliations

  1. Professor & Director, Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience, St. Louis University School of Medicine, St. Louis, Missouri, USA

    George T. Grossberg

  2. Co-Director of Neurology, SSM Neuroscience Institute, St. Louis, Missouri, USA

    Laurence J. Kinsella

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Newman, W.J. (2018). Mood Stabilizers, Anticonvulsants, and Anti-agitants. In: Grossberg, G., Kinsella, L. (eds) Clinical Psychopharmacology for Neurologists. Springer, Cham. https://doi.org/10.1007/978-3-319-74604-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74604-3_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74602-9

  • Online ISBN: 978-3-319-74604-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation